Normal view MARC view ISBD view

Clinicopathologic study and outcome analysis of thyroid lymphomas: Experience from a tertiary cancer center

In Head and Neck
By: Katna R.
Contributor(s): Nair R | DCruz AK | Prabhash K | Laskar S | Menon H | Sengar M | Shet T | .
Material type: materialTypeLabelArticleSeries: Vol 35 Issues 2.Publisher: 2013Description: 165-171.Subject(s): International Prognostic Index | Thyroid lymphomas | Clinicopathologic study | DDC classification: In: Head and NeckSummary: BACKGROUND: The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas. METHODS: The lymphoma clinic database was retrospectively reviewed to collect information on patients diagnosed with thyroid lymphomas. Tissue microarrays were constructed in 37 patients for evaluation of germinal center (CD10/bcl-6) and activated B-cell immunophenotype markers (FoxP1, Mum1). RESULTS: During 2000 to 2010, 64 of 5668 patients registered at our lymphoma clinic were diagnosed with thyroid lymphoma (1.7%). Complete response (CR) to treatment was seen in 80.7%. The germinal center immunophenotype and activated B-cell immune phenotype did not influence the prognosis. FoxP1, however, was associated with poor treatment response and decreased survival. CONCLUSIONS: Advanced International Prognostic Index (IPI) score and combined-modality treatment emerged as significant prognostic
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR12370

BACKGROUND: The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas.

METHODS: The lymphoma clinic database was retrospectively reviewed to collect information on patients diagnosed with thyroid lymphomas. Tissue microarrays were constructed in 37 patients for evaluation of germinal center (CD10/bcl-6) and activated B-cell immunophenotype markers (FoxP1, Mum1).

RESULTS: During 2000 to 2010, 64 of 5668 patients registered at our lymphoma clinic were diagnosed with thyroid lymphoma (1.7%). Complete response (CR) to treatment was seen in 80.7%. The germinal center immunophenotype and activated B-cell immune phenotype did not influence the prognosis. FoxP1, however, was associated with poor treatment response and decreased survival.

CONCLUSIONS: Advanced International Prognostic Index (IPI) score and combined-modality treatment emerged as significant prognostic

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha